RYTM Rhythm Pharmaceuticals Forecast, Technical & Fundamental Analysis
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases... Show more
RYTM is expected to report earnings to fall 1.98% to -81 cents per share on August 04
Q2'26
Est.
$-0.81
Q1'26
Est.
$-0.83
Q4'25
Beat
by $0.09
Q3'25
Missed
by $0.11
Q2'25
Missed
by $0.08
The last earnings report on May 05 showed earnings per share of -82 cents, meeting the estimate of -82 cents. With 201.24K shares outstanding, the current market capitalization sits at 7.37B.
A.I. Advisor
published General Information
General Information
a developer of peptide therapeutics for metabolic diseases
A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with MGX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then MGX could also see price increases.
RYTM in upward trend: 10-day moving average broke above 50-day moving average on June 17, 2026
The 10-day moving average for RYTM crossed bullishly above the 50-day moving average on June 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 12, 2026. You may want to consider a long position or call options on RYTM as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for RYTM just turned positive on June 15, 2026. Looking at past instances where RYTM's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
RYTM moved above its 50-day moving average on June 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 224 cases where RYTM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for RYTM moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
RYTM broke above its upper Bollinger Band on June 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (59.880) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). RYTM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (32.787) is also within normal values, averaging (434.181).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
